Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...
William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...
Zacks Investment Research on MSN1d
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...
This was the stock's second consecutive day of losses.
Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...
The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.
NEW YORK – Bristol Myers Squibb and 2seventy Bio on Monday entered into a merger agreement in which BMS will acquire 2seventy for $286 million, ending the firms' cost-sharing agreement for the ...
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback